ArticleJournal of experimental & clinical cancer research : CR2026

PROTAC-mediated degradation of Bcl-xL potentiates target therapy in preclinical melanoma models.

Elisabetta Valentini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.